If you’ve ever tried to pin down your true PBM cost, you already know the answer isn’t simple.
On paper, pharmacy benefit managers (PBMs) look like cost-saving partners. In practice, the way they structure pricing, negotiate rebates, and manage prescription drug claims can quietly shape your hospice’s margins more than almost any other vendor relationship.
For hospice leaders operating under a fixed Medicare per-diem, every dollar spent on medications comes directly out of your operating margin. That makes understanding PBM cost less of an accounting exercise and more of a strategic imperative.
Let’s break it down clearly.
Pharmacy benefit managers, often called PBMs, act as intermediaries between health plans, pharmacies, and drug manufacturers. In traditional markets, PBMs negotiate rebates, manage prescription drug benefits, and process prescription drug claims on behalf of plan sponsors and health insurers.
In hospice, the structure looks a little different.
A hospice PBM may:
All of that costs money. The question is how it’s priced and whether the structure aligns with your financial reality.
Unlike large health plans where prescription drug costs are offset by rebates and complex benefit designs, hospice organizations operate under a fixed daily reimbursement from Medicare or Medicaid. There’s no wiggle room. Pharmacy spend must fit inside that per-diem.
Understanding your PBM cost starts with knowing which pricing structure you’re under.
Some PBMs offer a flat per-patient per-day rate covering medications and services.
On the surface, this feels predictable. One number. One invoice. Fewer surprises.
But bundled models can hide risk. If utilization trends shift or higher-cost specialty drugs enter the picture, the PBM may narrow formularies or push financial exposure back onto the hospice through non-formulary pricing.
Predictability is helpful. Hidden guardrails are not.
Spread pricing is where PBMs generated significant scrutiny in broader healthcare markets.
In this model, the PBM bills the hospice one price but reimburses the pharmacy a lower amount, keeping the difference as revenue. That difference is called the “spread.”
The challenge is transparency.
If you cannot see what the PBM paid the pharmacy versus what you were billed, you cannot accurately measure your true PBM cost. Spread pricing can inflate prescription drug costs without the hospice realizing where the margin is being absorbed.
For organizations already operating on thin margins, that opacity matters.
In a pass-through model, the PBM passes the actual pharmacy acquisition and dispensing costs directly to the hospice and charges a clearly defined administrative fee per claim.
No hidden spread. No rebate retention games.
This structure gives hospice leaders something rare in pharmacy contracting: visibility.
With transparent claim-level data, you can:
When margins are tight, clarity becomes currency.
Formularies are more than drug lists. They are financial levers.
Some PBMs negotiate aggressively with drug manufacturers and pharmacies, particularly among the largest PBMs in the broader health insurance market. In hospice, however, restrictive formularies can create unintended consequences.
If a needed medication is excluded:
What looks like cost control on paper can increase operational burden and erode staff efficiency.
PBM cost is not just about drug prices. It’s about the downstream effect on your team.
Many large PBMs operate under vertically integrated structures alongside health insurers, specialty pharmacies, and mail order pharmacy services.
In commercial insurance markets, this integration allows PBMs to negotiate rebates and manage benefit plans at scale. In hospice, however, the economics are different.
Hospices are not passing drug costs to members through premiums or cost sharing. You’re absorbing the expense inside a fixed reimbursement structure.
That makes it essential to ask:
Without transparency, vertical integration can blur accountability.
Under the Medicare hospice benefit, organizations receive a set daily rate intended to cover all services, including medications related to the terminal diagnosis.
If pharmacy spend creeps upward because of opaque PBM services, the impact is immediate.
Higher drug spend means:
Contrast that with a transparent model where clinical pharmacists are embedded in the workflow, helping deprescribe unnecessary medications and optimize regimens.
When PBM structure supports clinical insight instead of obscuring costs, margins stabilize.
Transparency allows hospice leaders to see:
With that visibility, you can compare models, renegotiate contracts, and make data-driven decisions.
Technology plays a role here too. When pharmacy management isn’t siloed, leaders can evaluate true PBM cost within the broader operational picture.
Clarity reduces surprises. Surprises erode margins.
See how BetterRX can help your hospice understand PBM costs today.
A hospice pharmacy benefit manager negotiates drug prices with pharmacies, processes prescription drug claims, manages formularies, and provides clinical and utilization tools for hospices.
Hospices pay PBMs because they handle pharmacy contracting, benefit management, and technology support that can reduce overall drug spend and staff burden.
PBMs serving hospices usually use one or more structures:
Each structure produces a different PBM cost profile.
In a pass-through model, the PBM passes the exact pharmacy acquisition and dispensing costs directly to the hospice and adds a clearly defined administrative fee per claim.
This removes hidden markups and allows hospices to benefit directly from improvements in drug selection, utilization, and shipping efficiency.
Restrictive formularies may exclude higher-cost medications, then charge steep non-formulary rates when those drugs are required.
This can increase total spend, add prior authorization burden, and raise nurse workload, indirectly increasing operational cost.
Under Medicare and Medicaid, hospices receive a fixed daily payment that must cover all services, including medications.
If PBM pricing is opaque or inflated, pharmacy spend can consume a disproportionate share of that per-diem. Transparent pricing models support predictable budgeting and stronger margins.
Transparency allows you to see what was paid, what was billed, and where fees apply.
With that insight, hospices can:
Clarity empowers control.
PBM cost in hospice is not just about the price of pills. It’s about structure, transparency, and alignment with your financial reality.
In a reimbursement model that leaves no room for waste, the wrong PBM structure quietly drains margin. The right one strengthens it.
If your organization cannot clearly explain how its PBM generates revenue, that’s your first red flag.
BetterRX believes pharmacy should be transparent, clinically integrated, and built specifically for hospice. When pharmacy management supports your team instead of complicating it, you protect margins and improve patient comfort at the same time. Learn more about BetterRX today.
About BetterRX